Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction

Gynecologic Oncology

Volumn 118, Issue 1, 2010, Pages 43-46

  McLean, Kate A ^a   Shah, Chirag A ^a   Thompson, Sara A ^a   Gray, Heidi J ^a   Swensen, Ron E ^a   Goff, Barbara A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Elderly; Neoadjuvant chemotherapy; Ovarian cancer; Primary cytoreduction; Survival

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; MEGESTROL ACETATE; MELPHALAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADJUVANT THERAPY; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; FEMALE; HUMAN; ILEUS; KAPLAN MEIER METHOD; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEPSIS; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; WOUND INFECTION;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77953288380     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.03.002     Document Type: Article

References (19)

1. Yancik R., Ries L.G., and Yates J.W. Ovarian cancer in the elderly: an analysis of surveillance, epidemiology and end results program data. Am J Obstet Gynecol 154 (1986) 639-647
2. Pectasides D., Farmakis D., and Koumarianou A. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. Oncology 68 (2005) 64-70
3. Lewis J., Kilgore M., Goldman D., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
4. Uyar D., Frasure H., Markman M., and von Gruenigen V.E. Treatment patterns by decade of life in elderly women (≥ 70 years of age) with ovarian cancer. Gynecol Oncol 98 (2005) 403-408
5. Markman M., Lewis J., Saigo P., et al. Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experience. Cancer 71 (1993) 634-637
6. Sundararajan V., Hershman D., Grann V., et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population based study. J Clin Oncol 20 (2002) 173-178
7. Moore K., Reid M., Fong D., et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?. Gynecol Oncol 110 (2008) 133-139
8. Cloven N., Manetta A., Berman M., Kohler M., and DiSaia P. Management of ovarian cancer in patients older than 80 years of age. Gynecol Oncol 73 (1999) 137-139
9. Marchetti D., Lele S., and Priore R. Treatment of advanced ovarian carcinoma in the elderly. Gynecol Oncol 49 (1993) 86-91
10. Diaz-Montes D., Zahurak M., and Giuntoli R. Surgical care of elderly women with ovarian cancer: a population based perspective. Gynecol Oncol 99 (2005) 352-357
11. Ries L. Ovarian Cancer. Survival and treatment differences by age. Cancer 71 (1993) 524-529
12. Alberts D.F., Dahlberg S., Green S.J., et al. Analysis of patient age as an independent prognostic factor for survival in phase III study of cisplatin-cyclophosphamide versis carboplatin-cyclephoshpamide in stages III (suboptimal) and stage IV ovarian cancer. A Southwest Oncology Group study. Cancer 71 (1993) 618-627
13. Chan J., Loizzi V., Lin Y., Osann K., Brewster W., and DiSaia P. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. Obstet Gynecol 102 (2003) 156-161
14. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
15. Alphs H.H., Zahurak M.L., Bristow R.E., and Diaz-Montes T.P. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol 103 (2006) 1048-1053
16. Chi D.S., Franklin C.C., Levine D.A., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94 3 (2004) 650-654
17. Bristow R.E., Eisenhauer E.L., Santillan A., and Chi D.S. Delaying the primary surgery effort in advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104 2 (2007) 480-490
18. Rose P., Nerenstone S., Brady M., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. NEJM 351 (2004) 2489-2497
19. Armstrong D., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. NEJM 354 (2006) 34-43